Edoxaban - NDSRI's
References
FAQ's
References
- Ohta, Toshiharu; Komoriya, Satoshi; Yoshino, Toshiharu; Uoto, Kouichi; Nakamoto, Yumi; Naito, Hiroyuki; Mochizuki, Akiyoshi; Nagata, Tsutomu; Kanno, Hideyuki; Haginoya, Noriyasu; et al, Diamine Derivatives, Daiichi Pharmaceutical Co., Ltd., Japan, EP1405852B1, August 1, 2012
- He, Ling; Kochan, Jarema; Lin, Min; Vandell, Alexander; Brown, Karen; Depasse, Francois, Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay, Thrombosis Research, Volume: 155,Pages: 121-127, 2017
Frequently Asked Questions
Are Edoxaban impurities monitored during clinical trials?
Yes, impurities in Edoxaban are closely monitored during clinical trials to assess their impact on safety, efficacy, and patient tolerability. Any significant impurities are thoroughly evaluated and controlled.
Can Edoxaban impurities interact with other medications?
Certain impurities in Edoxaban may have the potential to interact with other medications. Drug-drug interaction studies help evaluate such possibilities and ensure safe co-administration.
Are Edoxaban impurities more likely to form under specific storage conditions?
Storage conditions can influence the formation of impurities in Edoxaban. Proper storage, including temperature control and protection from light and moisture, is essential to minimize impurity formation.
What are the temperature conditions required to store Edoxaban impurities?
Edoxaban impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.